SGLT2抑制剂在心力衰竭患者中蛋白质组学机制特征的验证
本研究在EMPEROR项目中发现队列(1134例,1283种蛋白)基础上,于验证队列(1120例,2155种蛋白)中验证恩格列净对循环蛋白的影响。验证队列中25种蛋白差异富集(组间差异≥15%,FDR<1%),涉及自噬、线粒体健康、铁动员和肾小管钠处理等机制,与发现队列一致。
要点
- 恩格列净在12周时显著改变25种与心脏或肾脏相关的循环蛋白。
- 这些蛋白涉及自噬促进、线粒体ATP产生、铁动员和肾小管钠处理。
- 机制特征在发现与验证队列中高度重复,与实验性SGLT2抑制剂效应一致。
核心结论
- 恩格列净在心力衰竭患者中引发的蛋白质组学特征在验证队列中重现,与实验性SGLT2抑制剂效应一致。
研究设计与样本
- 基于EMPEROR项目的发现队列(1134例,1283种蛋白)和验证队列(1120例,2155种蛋白),均为双盲随机试验。
主要发现
- 验证队列中25种蛋白差异富集(≥15%组间差异,FDR<1%,12周),其中13种促进自噬,12种增强线粒体健康,7种促进铁动员,3种影响肾小管钠处理,9种有心脏或肾脏修复作用。
- 阈值降至≥10%时,额外58种蛋白差异富集,但生物学特征不变。
临床怎么用
- 这些机制特征支持SGLT2抑制剂在心力衰竭患者中通过促进自噬、恢复线粒体健康、促进铁动员和影响肾小管离子重吸收发挥有益作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert a distinctive pattern of direct biological effects on the heart and kidney under experimental conditions, but the meaningfulness of these signatures for patients with heart failure has not been fully defined. OBJECTIVES: We performed the first mechanistic validation study of large-scale proteomics in a double-blind randomized trial of any treatment in patients with heart failure. METHODS: In a discovery cohort from the EMPEROR (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and Reduced Ejection Fraction) program, we studied the effect of randomized treatment with placebo or empagliflozin on 1,283 circulating proteins in 1,134 patients with heart failure with a reduced or preserved ejection fraction. In a validation cohort, we expanded the number to 2,155 assessed proteins, which were measured in 1,120 EMPEROR participants who had not been studied previously. RESULTS: In the validation cohort, 25 proteins were the most differentially enriched by empagliflozin (ie, ≥15% between-group difference and false discovery rate <1% at 12 weeks with known effects on the heart or kidney): 1) 13 proteins promote autophagy and other cellular quality-control functions (IGFBP1, OTUB1, DNAJB1, DNAJC9, RBP2, IST1, HSPA8, H-FABP, FABP6, ATPIFI, TfR1, EPO, IGBP1); 2) 12 proteins enhance mitochondrial health and ATP production (UMtCK, TBCA, L-FABP, H-FABP, FABP5, FABP6, RBP2, IST1, HSPA8, ATPIFI, TfR1, EPO); 3) 7 proteins augment cellular iron mobilization or erythropoiesis (TfR1, EPO, IGBP1, ERMAP, UROD, ATPIF1, SNCA); 4) 3 proteins influence renal tubular sodium handling; and 5) 9 proteins have restorative effects in the heart or kidneys, with many proteins exerting effects in >1 domain. These biological signatures replicated those observed in our discovery cohort. When the threshold for a meaningful between-group difference was lowered to ≥10%, there were 58 additional differentially enriched proteins with actions on the heart and kidney, but the biological signatures remained the same. CONCLUSIONS: The replication of mechanistic signatures across discovery and validation cohorts closely aligns with the experimental effects of SGLT2 inhibitors. Thus, the actions of SGLT2 inhibitors-to promote autophagy, restore mitochondrial health and production of ATP, promote iron mobilization and erythropoiesis, influence renal tubular ion reabsorption, and normalize cardiac and renal structure and function-are likely to be relevant to patients with heart failure. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction [EMPEROR-Preserved], NCT03057951; EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced], NCT03057977).
引用
- Packer M, Ferreira JP, Butler J, et al. Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program. J Am Coll Cardiol. 2024. PMID: 39217550. doi:10.1016/j.jacc.2024.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。